Thalidomide: dermatological indications, mechanisms of action and side-effects.
about
A Review of the Efficacy of Thalidomide and Lenalidomide in the Treatment of Refractory Prurigo NodularisExploiting large-scale drug-protein interaction information for computational drug repurposing.A framework to identify gene expression profiles in a model of inflammation induced by lipopolysaccharide after treatment with thalidomideCause for controversy? Infliximab in the treatment of ulcerative colitis: an update.The genetics of pyoderma gangrenosum and implications for treatment: a systematic review.Thalidomide-induced orofacial neuropathy.Nitric oxide rescues thalidomide mediated teratogenicity.Prognosis of refractory neurosarcoidosis altered by thalidomide: a case reportThe origin of life and the left-handed amino-acid excess: the furthest heavens and the deepest seas?Effect of thalidomide on nitric oxide production in lipopolysaccharide-activated RAW 264.7 cells.Efficacy and safety of lenalidomide for refractory cutaneous lupus erythematosus.What can we learn from the thalidomide experience: an ophthalmologic perspective.Thalidomide: mechanisms of action.Targeting the IL-1 family members in skin inflammation.Treatment options for alopecia: an update, looking to the future.Practical guidelines for the use of steroid-sparing agents in the treatment of chronic pruritus.Systemic use of non-biologic agents in orofacial diseases: other immunomodulatory agents.Lenalidomide treatment of cutaneous lupus erythematosus: the Mayo Clinic experience.Neurological and Neuropsychiatric Adverse Effects of Dermatologic Medications.Lenalidomide for refractory cutaneous manifestations of pediatric systemic lupus erythematosus.Thalidomide improves clinical symptoms of primary cutaneous amyloidosis: report of familiar and sporadic cases.Thalidomide as a Potential HIV Latency Reversal Agent: Is It the Right Time to Forget the Ancestral Sins?Case report on a patient with lupus panniculitis.Langerhans' cell histiocytosis of the temporal bone: A case report.Anticancer agents against malaria: time to revisit?Thalidomide for the control of severe paraneoplastic pruritus associated with Hodgkin's disease.Effect of proteasome inhibitors with different chemical structures on the ubiquitin-proteasome system in vitro.Thalidomide: Still an important second-line treatment in refractory cutaneous lupus erythematosus?Lower-dose thalidomide therapy effectively treats cutaneous lupus erythematosus but is limited by neuropathic toxicity.Facets of lupus erythematosus: panniculitis responding to thalidomide.Thalidomide, semen distribution, teratogenicity... and cost.Thalidomide for treatment of intestinal involvement of juvenile-onset Behçet disease.Thalidomide treatment in cutaneous lesions of systemic lupus erythematosus: a multicenter study in China.Refractory aphthous ulceration treated with thalidomide: a report of 10 years' clinical experience.Self-disproportionation of enantiomers of thalidomide and its fluorinated analogue via gravity-driven achiral chromatography: mechanistic rationale and implications.A case of granuloma faciale successfully treated with oral prednisone, tranilast and thalidomide.The roles of neutrophil serine proteinases in idiopathic inflammatory myopathies.Treatment strategies for alopeciaThalidomide Embryopathy: An Enigmatic Challenge
P2860
Q26747036-50A56337-5AEB-45E0-AAB7-E89F0D1549C3Q30582560-53AE8E5C-184F-4304-917C-C1334F4B1F10Q34303157-0D0A08C8-B8AA-4D5C-8262-CD952574F8E4Q35026302-A117CBB9-69B8-46B9-9A5E-04A77D96C737Q35371636-29BD10DF-B548-453D-8591-DBDC96B9791FQ35642110-20B2094A-A249-454C-92FA-716A179287DEQ36247884-24F400DC-16A5-42C8-A57B-4E12A6A544F7Q36473644-7905D8B4-0953-407A-B829-60DA2A3B173FQ36632822-F8EF2BD2-F107-4AA0-9477-7FA3368AAD74Q36727915-336D51F4-1F62-407D-8F3A-83A499717FB3Q36907616-0E0C416D-BF2B-4FC9-A8FA-EC8BC8D76B89Q37019889-56D540EB-A513-4402-A416-7D87684E1AABQ37147933-97C8FD30-C1B4-4A64-90D4-34309A78A300Q37820911-4DC0BA45-6749-4163-BBD1-4F48FD42AA63Q38010773-8E638B30-CBDB-4ECB-9A6E-580D75154691Q38095599-AAFA5CC7-3A02-4C55-91F2-1B8366E3C2AEQ38136748-9B70CF5F-BA65-4170-8B39-9DE963B1478FQ38731966-6FC9971C-A757-455D-B911-88A858426F10Q39004668-269B0992-DA65-4AD6-9D05-9F9908BDEA8BQ39005980-FB933E10-8704-48F8-B69E-6F6F99E15BBCQ39226011-AF1C6BCA-FB1C-4BA5-8D26-86650DD71827Q40069617-B4B6CEDB-5E4C-44FB-8402-AE8F512F2F8CQ41918052-0C8C025F-A12E-4A41-83EF-E7865B9D6C84Q42290629-E58D90E1-8B83-4DC4-B1F5-E3FB1E331640Q42488257-F3F08120-23D7-4BB7-AFAE-859473B50BAEQ43128687-3C8419AE-3305-4B7E-B805-F214878F5F4DQ43177689-F3DEAB1E-E511-4887-815C-117CE04B0264Q44443369-0ECB4040-6862-47C0-812F-89B13FAAF132Q46001895-6242E774-B30E-40EA-BFBA-3BE3760384ABQ46852985-E7369EBA-7D0F-4B83-BC4C-9D075DFACD6AQ46918579-C1B060AF-030E-4FF1-BDE2-8D491442B05BQ46921942-2D93B796-1B45-4E5F-84F1-0FC407FD9DF6Q47865124-D0CC6A8D-42BB-4DEA-A871-2FFE16ED99C4Q53705358-69164695-DA2A-44C1-9C36-ECBB6F6C7518Q55020037-AADB8921-AC3D-42C7-AAF9-4ED5AEDF7727Q55152341-7317F90B-7CB0-478B-88DC-673161A51D45Q55457333-8454494E-2904-4F4B-8FB0-733D15C386BDQ56991024-1D70F447-A5FA-4B13-948E-E40510385194Q57129133-716A3E12-5EC3-4AF3-B354-B5A9E5157F38
P2860
Thalidomide: dermatological indications, mechanisms of action and side-effects.
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
2005年论文
@zh
2005年论文
@zh-cn
name
Thalidomide: dermatological indications, mechanisms of action and side-effects.
@ast
Thalidomide: dermatological indications, mechanisms of action and side-effects.
@en
type
label
Thalidomide: dermatological indications, mechanisms of action and side-effects.
@ast
Thalidomide: dermatological indications, mechanisms of action and side-effects.
@en
prefLabel
Thalidomide: dermatological indications, mechanisms of action and side-effects.
@ast
Thalidomide: dermatological indications, mechanisms of action and side-effects.
@en
P2093
P2860
P1476
Thalidomide: dermatological indications, mechanisms of action and side-effects.
@en
P2093
P2860
P304
P356
10.1111/J.1365-2133.2005.06747.X
P407
P577
2005-08-01T00:00:00Z